SCHEMBL10104434

SCHEMBL10104434

COc1c(C)cc(C(C)(C)C)cc1CN(C)C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 3/20 0.56
CYP1A2 P05177 3/20 0.46
ALOX15 P16050 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
CYP2D6 P10635 3/20 0.39
TSHR P16473 1/20 0.39
CYP2C9 P11712 1/20 0.38
HIF1A Q16665 1/20 0.38
KDM4E B2RXH2 2/20 0.37
POLB P06746 2/20 0.34
MEN1 O00255 2/20 0.34
ALDH1A1 P00352 2/20 0.34
KMT2A Q03164 2/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
G6PD P11413 1/20 0.34
PABPC1 P11940 1/20 0.34
HKDC1 Q2TB90 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10104475 0.86 CYP2C19 (0.41) CYP2C19CYP1A2ALOX15MAPK1HTT
SCHEMBL10104511 0.85 CYP3A4 (0.42) CYP2C19CYP1A2ALOX15MAPK1HTT
SCHEMBL1935976 0.83 CYP2C19 (0.53) CYP2C19CYP1A2ALOX15MAPK1HTT
SCHEMBL12401769 0.83 CYP2C19 (0.53) CYP2C19CYP1A2ALOX15MAPK1HTT
SCHEMBL13130527 0.81 CYP2C19 (0.50) CYP2C19CYP1A2ALOX15MAPK1HTT
SCHEMBL13458465 0.81 CYP2C19 (0.54) CYP2C19CYP1A2ALOX15MAPK1HTT
SCHEMBL13452244 0.80 DHFR (0.41) CYP2C19CYP1A2CYP2D6TSHRCYP2C9
SCHEMBL14943430 0.80 TSHR (0.40) TSHRKDM4EPOLBMEN1ALDH1A1
SCHEMBL12929955 0.79 MAPT (0.43) CYP2C19CYP1A2CYP2D6CYP2C9HIF1A
SCHEMBL1936804 0.77 CYP2C19 (0.50) CYP2C19CYP1A2ALOX15MAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946438-B2 Benzamides, production thereof, and use thereof as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-03 US disclosed
US-8778929-B2 Substituted heteroaryl inhibitors of B-RAF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-15 US disclosed
US-20140187539-A1 NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-03 US disclosed
US-8735579-B2 Benzamides, production thereof, and use thereof as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-05-27 US disclosed
US-8653087-B2 Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-18 US disclosed
US-20120094975-A1 PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-19 US disclosed
US-20110312939-A1 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140187539-A1 NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS HRH2, HRH1, HRH4 CYP2C19 139/4885CYP1A2 46/4885ALOX15 931/4885
US-20110312939-A1 NEW CHEMICAL COMPOUNDS CCNA1, CCNT1, MKI67 CYP2C19 818/4885CYP1A2 174/4885ALOX15 1847/4885
US-20120094975-A1 PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS CCNT1, CCNA1, CCND1 CYP2C19 637/4885CYP1A2 604/4885ALOX15 1808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.